Drug prescription patterns in patients with Alzheimer's disease in an urban neuro-specialty clinic in Western India

Joshi, Anuradha; Upadhyay, Henil; Parekh, Nidhi; Shah, S; Parekh, Kinnari

doi:10.5455/njppp.2019.9.0828114082019

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The details and protocols of neuropsychological assessment are described in a previous report [ 66 ]. The diverse interpretation of the MMSE scores and their relationship with the severity of dementia were depicted as several steps [ 3 , 67 , 68 , 69 ]. Using one of the ranging methods of MMSE, we split the participants into three groups: normal, with a score range from 24 to 30; mild dementia, with a score range from 20 to 23; and moderate to severe dementia, with a score range below 19 [ 37 ].…”

Section: Methodsmentioning

confidence: 99%

“…The development of Alzheimer’s disease (AD), the most common form of dementia, is slow and persistent, with a pre-symptom stage lasting over several years to decades [ 1 , 2 , 3 , 4 ]. As of 2023, the prevalence of Alzheimer’s dementia among the older population (aged 65 years and older) in the United States is estimated to be approximately 6.7 million individuals [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The QPLEX™ Plus Assay Kit for the Early Clinical Diagnosis of Alzheimer’s Disease

Shin

Lee³

et al. 2023

IJMS

View full text Add to dashboard Cite

We recently developed a multiplex diagnostic kit, QPLEX™ Alz plus assay kit, which captures amyloid-β1-40, galectin-3 binding protein, angiotensin-converting enzyme, and periostin simultaneously using microliters of peripheral blood and utilizes an optimized algorithm for screening Alzheimer’s disease (AD) by correlating with cerebral amyloid deposition. Owing to the demand for early AD detection, we investigate the potential of our kit for the early clinical diagnosis of AD. A total of 1395 participants were recruited, and their blood samples were analyzed with the QPLEX™ kit. The average of QPLEX™ algorithm values in each group increased gradually in the order of the clinical progression continuum of AD: cognitively normal (0.382 ± 0.150), subjective cognitive decline (0.452 ± 0.130), mild cognitive impairment (0.484 ± 0.129), and AD (0.513 ± 0.136). The algorithm values between each group showed statistically significant differences among groups divided by Mini-Mental State Examination and Clinical Dementia Rating. The QPLEX™ algorithm values could be used to distinguish the clinical continuum of AD or cognitive function. Because blood-based diagnosis is more accessible, convenient, and cost- and time-effective than cerebral spinal fluid or positron emission tomography imaging-based diagnosis, the QPLEX™ kit can potentially be used for health checkups and the early clinical diagnosis of AD.

show abstract